Enfortumab vedotin plus pembrolizumab improved EFS, OS, and pCR rates in MIBC patients ineligible for cisplatin-based chemotherapy. The combination therapy showed a median EFS and OS that were not ...
The study results reflect the effect of surgery with lymph node dissection alone in patients with high-grade invasive bladder cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback